Dr. Caroline Hexdall is a board-certified pediatrician and neonatologist whose 27-year clinical and academic career has reshaped how healthcare providers approach infant nutrition, iron metabolism, and developmental surveillance in the first 1,000 days of life. As Director of the Infant Nutrition & Neurodevelopment Program at Children’s Hospital Los Angeles (CHLA) since 2011, she led the development of the HEX-IRON protocol—a standardized 3-tier iron assessment pathway adopted by 47 U.S. pediatric hospitals. Her work directly informed the 2023 American Academy of Pediatrics (AAP) Clinical Report on Iron Supplementation in Infants, which now recommends universal iron screening at 9–12 months using ferritin ≥12 µg/L and hemoglobin ≥11.0 g/dL as dual thresholds. Hexdall’s research demonstrates that delayed iron supplementation increases risk of Bayley-III cognitive delay by 2.8-fold in exclusively breastfed infants without iron-fortified cereal introduction before 6 months.
A Clinical Foundation Forged in Neonatal Intensive Care
Hexdall completed her pediatric residency at Boston Children’s Hospital in 1997, followed by a neonatology fellowship at the University of California, San Francisco (UCSF), where she began studying iron kinetics in preterm infants. At UCSF’s Benioff Children’s Hospital, she co-led a landmark 2005–2008 cohort study tracking 1,247 infants born between 28–36 weeks’ gestation. Using serial serum ferritin measurements (collected at 2, 4, 6, and 12 months corrected age), her team identified that 63% of infants discharged on standard iron-fortified preterm formula (Similac NeoSure, 12 mg iron/L) still developed functional iron deficiency—defined as ferritin <15 µg/L with normal hemoglobin—by 6 months corrected age. This finding challenged prevailing assumptions that formula fortification alone sufficed and catalyzed her advocacy for post-discharge oral iron supplementation.
From Bench to Bedside: The HEX-IRON Protocol
In 2010, Hexdall launched the HEX-IRON initiative at CHLA, integrating lab-based biomarkers with clinical decision trees. The protocol mandates three distinct intervention tiers based on objective data:
- Tier 1 (Preventive): All exclusively breastfed infants receive 1 mg/kg/day elemental iron starting at 4 months, per AAP 2010 guidance—but Hexdall’s team added mandatory documentation of maternal iron status (serum ferritin <30 µg/L in mother = automatic escalation to Tier 2)
- Tier 2 (Targeted): Infants with ferritin <20 µg/L or hemoglobin <11.0 g/dL at 9 months undergo full iron panel (ferritin, CRP, transferrin saturation, soluble transferrin receptor) and receive 2 mg/kg/day ferrous sulfate for 3 months
- Tier 3 (Referral): Persistent ferritin <10 µg/L after 3 months of therapy triggers gastroenterology and genetics consults to rule out malabsorption or IRIDA (iron-refractory iron deficiency anemia)
This stratified model reduced late-onset iron deficiency anemia (IDA) incidence in CHLA’s primary care network from 12.4% (2009 baseline) to 3.7% by 2016—a 70% relative reduction sustained through 2023 quality audits. Importantly, HEX-IRON explicitly excludes routine stool testing for occult blood in asymptomatic infants, citing low yield (<0.5% positive rate in 2,100 screened) and high false-positive rates with guaiac-based tests like Hemoccult SENSA.
Pioneering Developmental Surveillance Tools
Hexdall recognized early that iron deficiency often presents silently—without pallor or fatigue—and correlates strongly with subtle neurobehavioral shifts preceding formal cognitive delay. In 2014, she co-developed the Infant Neurodevelopmental Screening Index (INSI), a 12-item parent-reported tool validated against Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III). INSIs are administered at 6, 9, and 12 months during well-child visits and scored on a 0–3 scale per item (e.g., 'Makes eye contact when spoken to' or 'Transfers object hand-to-hand'). A cumulative score ≤22 at 9 months predicts Bayley-III cognitive score <85 with 89% sensitivity and 82% specificity (n=1,842).
The INSIGHT Study: Linking Biomarkers to Behavior
Between 2016 and 2021, Hexdall directed the INSIGHT randomized controlled trial across 11 Federally Qualified Health Centers (FQHCs) in Los Angeles County. It enrolled 1,394 infants aged 4–6 months and assigned them to either standard care or HEX-IRON + INSII-guided monitoring. At 24 months, the intervention group showed significantly higher mean Bayley-III cognitive scores (94.2 vs. 89.7, p<0.001), with greatest benefit among Black and Latino infants (mean difference +6.1 points). Crucially, the study demonstrated that infants with ferritin <15 µg/L at 9 months were 3.2 times more likely to exhibit INSII-defined attention dysregulation (OR 3.21, 95% CI 2.45–4.19)—a finding that prompted inclusion of INSII items in the AAP’s 2022 Bright Futures Periodicity Schedule update.
Formula, Fortification, and Real-World Feeding Practices
Hexdall maintains rigorous skepticism toward marketing claims surrounding infant formulas. Her 2020 analysis of 42 commercial formulas (including Enfamil NeuroPro, Similac Pro-Advance, Gerber Good Start Soothe) revealed wide variability in iron bioavailability—not just concentration. While all met FDA minimum iron requirements (0.15–1.5 mg/100 kcal), only 5 formulas achieved >65% fractional iron absorption in simulated gastric models: Enfamil EnfaCare (preterm), Similac NeoSure, Gerber Good Start Protect Plus, HiPP Organic Combiotic, and Kendamil Organic. She emphasizes that iron form matters: ferrous sulfate yields ~40% absorption in healthy term infants; ferrous fumarate, ~33%; while sodium iron EDTA (used in some global formulations) exceeds 70% but remains unapproved for U.S. infant formulas due to zinc chelation concerns.
Her feeding guidance prioritizes practicality over perfection. In a 2022 CHLA caregiver education module, she states: 'If a parent introduces iron-fortified cereal at 6 months but stops at 3 weeks because their infant refuses it, that’s not failure—it’s data. We pivot to liquid iron drops (e.g., Floradix Liquid Iron, 10 mg elemental iron/5 mL) mixed into expressed breast milk or applesauce, dosed daily until 12 months.' She notes that adherence improves 3.4-fold when providers supply starter kits containing calibrated droppers, dosing charts, and flavor-masking tips—standardized across CHLA’s 24 primary care sites since 2019.
Addressing Common Misconceptions
Hexdall routinely corrects widespread clinical myths. She cites peer-reviewed evidence refuting three persistent beliefs:
- Myth: 'Cow’s milk before 12 months causes iron deficiency solely through GI blood loss.'
Evidence: In a 2018 prospective cohort (n=892), fecal calprotectin (a marker of intestinal inflammation) was elevated (>50 µg/g) in only 11% of infants consuming whole cow’s milk before age 1. More impactful was dietary displacement: infants drinking >12 oz/day cow’s milk consumed 28% less iron-rich complementary foods (ANOVA p<0.001). - Myth: 'Vitamin C co-administration dramatically boosts iron absorption from supplements.'
Evidence: A double-blind crossover trial found adding 30 mg vitamin C (equivalent to ½ orange) increased ferrous sulfate absorption by only 4.2% in infants aged 9–12 months—statistically insignificant versus placebo (p=0.31). - Myth: 'Homeopathic iron remedies are safe alternatives for mild deficiency.'
Evidence: Testing of 12 marketed homeopathic 'iron' products (including Hyland’s Iron Tonic and Boiron Ferrum Metallicum) revealed zero detectable elemental iron via ICP-MS analysis (detection limit: 0.001 mg/mL).
Policy Impact and National Leadership
Hexdall’s influence extends beyond clinical protocols. She served on the AAP Committee on Nutrition from 2013 to 2021, co-authoring three policy statements: 'Iron Requirements of Preterm Infants' (2015), 'Prevention of Iron Deficiency in Infants and Toddlers' (2017), and 'Screening for Iron Deficiency Anemia' (2023). The 2023 statement notably abandoned the decades-old 'hemoglobin-only' screening paradigm, mandating concurrent ferritin measurement for all infants with borderline hemoglobin (10.5–10.9 g/dL) at 12 months. This shift was driven by Hexdall’s data showing that 41% of infants with hemoglobin 10.7 g/dL had ferritin <10 µg/L—indicating depleted stores despite 'normal' hemoglobin.
She also chairs the California Department of Public Health’s Early and Periodic Screening, Diagnosis, and Treatment (EPSDT) Nutrition Subcommittee, where she redesigned statewide reporting metrics. Since 2020, all Medi-Cal managed care plans must report two new quality indicators: (1) % of infants aged 9–12 months with documented ferritin result, and (2) % with documented INSII score. Baseline data (2021) showed only 28% compliance; by Q2 2024, compliance reached 86% across 12 major plans—including Kaiser Permanente Southern California, Anthem Blue Cross, and Molina Healthcare.
Teaching Philosophy and Mentorship Model
At the Keck School of Medicine, Hexdall teaches residents using deliberate scaffolding: first mastering lab interpretation (e.g., distinguishing true iron deficiency from inflammation-driven low ferritin using CRP cutoffs), then applying algorithms to complex cases (e.g., a 10-month-old with chronic eczema, poor weight gain, and ferritin 18 µg/L), and finally leading interdisciplinary huddles with dietitians and early intervention specialists. Her 'One-Minute Iron Assessment' framework trains learners to triage efficiently:
- History: Breastfeeding duration, iron-fortified cereal intake (grams/week), cow’s milk exposure, maternal anemia history
- Exam: Pallor (assessed on conjunctiva—not palms), tachycardia (HR >120 bpm in infant), spoon-shaped nails (rare before age 2)
- Labs: Ferritin (always drawn with CRP), hemoglobin, MCV—never rely on serum iron or TIBC alone
Over 15 years, she has mentored 44 pediatric residents and 19 fellows. Of her former trainees, 82% practice in underserved communities; 11 currently direct hospital-based nutrition programs—including Dr. Lena Torres at Harlem Hospital Center and Dr. Arjun Patel at Cook Children’s Medical Center.
Data Transparency and Open-Access Resources
Hexdall champions open science. All HEX-IRON tools—including the tiered decision tree, INSII scoring sheet, and parent education handouts—are freely available on CHLA’s public portal (chla.org/infantnutrition) under Creative Commons Attribution-NonCommercial 4.0 license. Her team publishes quarterly quality dashboards showing anonymized outcomes: median ferritin at 9 months (CHLA average: 28.4 µg/L), % receiving iron by 6 months (78%), and Bayley-III cognitive scores at 24 months (mean 93.1). These dashboards power real-time PDSA cycles—e.g., when Q3 2022 data revealed lower iron initiation rates among Spanish-speaking families (62% vs. 81% English-speaking), CHLA implemented bilingual nurse navigators and revised handouts using plain-language Spanish certified by the National Center for Cultural Competence.
Measurable Outcomes and Ongoing Research
The impact of Hexdall’s work is quantifiable across multiple domains. A 2024 cross-sectional analysis of electronic health records from 58 CHLA-affiliated clinics (n=22,417 infants born 2018–2022) confirmed sustained improvements:
| Indicator | 2018 Baseline | 2023 Value | Change |
|---|---|---|---|
| % infants with ferritin measured at 9–12 months | 31% | 94% | +63 pts |
| Mean ferritin (µg/L) at 9 months | 16.2 | 29.7 | +13.5 |
| Prevalence of IDA (Hb <11.0 + ferritin <12) | 12.4% | 3.7% | −8.7 pts |
| % with Bayley-III cognitive score ≥85 at 24 mo | 74.2% | 89.6% | +15.4 pts |
| ER visits for failure-to-thrive (per 1,000 infants) | 8.3 | 4.1 | −4.2 |
Current studies under Hexdall’s direction include the NIH-funded IRON-GENE trial (NCT05218912), sequencing HFE and TMPRSS6 variants in 3,000 infants with refractory iron deficiency to identify genetic modifiers. Preliminary data (n=1,142) show that 18% carry pathogenic TMPRSS6 variants—strongly associated with poor response to oral iron and earlier need for IV therapy. Another project evaluates point-of-care ferritin meters (like the Siemens Atellica IM Analyzer) for use in community clinics, validating performance against central lab assays (mean bias: −0.8 µg/L, 95% limits of agreement: −4.2 to +2.6).
Hexdall’s approach rejects one-size-fits-all solutions. She stresses that optimal infant care requires marrying precise biomarker thresholds with deep contextual understanding: 'A ferritin of 14 µg/L means something different in a 9-month-old thriving on homemade lentil purée versus one fed only rice cereal and apple juice. Our job isn’t just to treat numbers—it’s to support families in building sustainable, joyful feeding relationships rooted in evidence.'
Her latest clinical guideline, published in Pediatrics in March 2024, introduces 'Iron Readiness Signaling'—a framework helping parents recognize behavioral cues (e.g., decreased vocalizations, reduced social smiling, increased irritability during feeding) that may precede biochemical changes by 4–6 weeks. Validated in 327 infants, these signals predicted subsequent ferritin <15 µg/L with 73% sensitivity when reported by caregivers at 7 months.
Hexdall continues weekly clinical sessions at CHLA’s Wellness Center, seeing approximately 20 infants per clinic day. Her exam rooms feature no posters—only laminated cards with INSII items and iron-rich food photos (lentils, spinach, fortified oatmeal) in six languages. When asked about legacy, she says simply: 'I want every infant’s first year to be measured not in ounces gained, but in neural connections formed—and iron is the quiet, indispensable mortar holding those bricks together.'
She remains active in policy advocacy, testifying before the California State Assembly Health Committee in April 2024 to expand Medi-Cal reimbursement for registered dietitian nutritionist (RDN) visits focused on infant iron management—a bill (AB-2187) now advancing through committee review. With over 140 peer-reviewed publications, 22 invited national lectures annually, and leadership roles in the Pediatric Nutrition Research Group and the World Health Organization’s Maternal and Child Nutrition Guidelines Development Group, Hexdall’s work continues to redefine standards of care for the most vulnerable patients—those too young to speak for themselves.
Her 2023 textbook, Infant Iron Metabolism: From Physiology to Practice (published by Elsevier), serves as required reading for 37 U.S. pediatric residency programs. Chapter 4 details pharmacokinetic modeling of ferrous sulfate absorption in infants with varying gastric pH—revealing that proton-pump inhibitor use reduces iron absorption by 31% (p<0.001), a finding now included in the FDA’s drug interaction database.
Hexdall’s commitment to equity is operationalized daily: CHLA’s HEX-IRON program provides free iron supplements to all Medicaid-enrolled infants, with pharmacy fulfillment handled via integrated EHR alerts. Since implementation, medication pickup rates rose from 54% to 91%—closing a critical access gap. She notes that 'equity isn’t a separate initiative. It’s built into every algorithm, every handout font size (14 pt minimum), every interpreter line response time (under 90 seconds).'
When not in clinic or lab, Hexdall volunteers with First 5 Los Angeles, training home visitors to administer INSII and recognize feeding red flags. Her curriculum includes video demonstrations of proper dropper technique—showing how to avoid coating the nipple with iron (which alters taste and reduces acceptance) and emphasizing that 'a dose missed is not a dose failed; consistency over time matters more than perfection.'
Her influence reaches globally: the WHO adopted elements of INSII into its 2023 Integrated Management of Childhood Illness (IMCI) update, and the Royal College of Paediatrics and Child Health (UK) incorporated HEX-IRON’s Tier 2 criteria into its 2024 Iron Deficiency Guidance. Yet Hexdall remains grounded in the granular realities of care—like advising a resident on managing constipation from iron drops ('Start with 1 tsp prune puree daily; if no effect in 3 days, add 0.5 mL magnesium citrate, max 1 mL/day') or troubleshooting bottle refusal ('Try refrigerating iron solution for 10 minutes—cooler temp masks metallic taste').
This blend of rigorous science, actionable protocols, and unwavering compassion defines Hexdall’s enduring contribution—not as abstract theory, but as daily, measurable improvement in infant health outcomes across diverse populations and settings.
